Semaglutide, the blockbuster GLP-1 receptor agonist marketed under names like Ozempic (type 2 diabetes) and Wegovy (weight loss), has rapidly become one of the most consequential drugs in modern healthcare
Please note if you have Medicare, Medicaid, Tricare, Kaiser-Permenente or other insurance which does not currently cover weight-loss medications you may be automatically denied without a submission for approval
Obesity Statistics (2022): Globally : 890 million adults and 160 million adolescents are obese
Studies have demonstrated Semaglutides effectiveness in significant weight reduction
Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, Hadsell DL, Barrios RJ, Foster BA, et al